The young boy in the Pfizer trial was part of a study tracking the effectiveness of gene therapy for Duchenne muscular dystrophy using fordadistrogene movaparvovec, aimed at introducing a normal dystrophin gene into muscles.
DMD is a genetic disorder affecting newborns, with the Pfizer trial involving ten two to three-year-old boys to be monitored over five years, starting from 2022 to early 2029.
[
add
]
[
|
|
...
]